
|Videos|June 30, 2017
Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets
Author(s)Sara M. Tolaney, MD, MPH
This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses an early trial studying the CDK4/6 inhibitor abemaciclib for the treatment of brain metastases in patients with hormone receptor (HR)-positive HER2-negative breast cancer.
Tolaney presented the study results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
How Did Daraxonrasib Double Survival in Pretreated Metastatic Pancreatic Cancer?
2
Zongertinib Yields Enduring Activity in Frontline HER2+ NSCLC Trial
3
Novel Drug Class is Convenient and Meaningful in Multiple Myeloma Landscape
4
Belantamab Mafodotin Combo for R/R Multiple Myeloma Earns Approval in China
5

























































